pith. sign in

arxiv: 2605.24346 · v1 · pith:APO7WOM6new · submitted 2026-05-23 · 📊 stat.ME

Using the target trial framework for combining information: external comparator analyses and other applications

Lawson Ung , Miguel A. Hern\'an , Issa J. Dahabreh This is my paper

Pith reviewed 2026-06-30 13:42 UTC · model grok-4.3

classification 📊 stat.ME
keywords target trialcausal inferenceexternal comparatorgeneralizabilitytransportabilitydata integrationobservational studies
0
0 comments X

The pith

The target trial framework should add an explicit sampling model for the target population when combining data from multiple sources for causal questions.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper proposes extending the target trial framework by specifying the target population together with its sampling model as a new component. This extension matters for analyses that merge information across sources, such as external comparator studies or transportability analyses, because the population definition shapes eligibility criteria, the causal model, the contrasts of interest, and strategies for identifying effects. The framework further requires mapping data elements from each source onto one common target trial. That mapping process tends to expose misalignments in how eligibility, treatment assignment, or receipt are defined across sources. When misalignments prove irreconcilable, the framework directs analysts toward different data sources or prospective data collection rather than ad-hoc fixes.

Core claim

The target trial framework can be used to plan and report causal analyses that combine information from multiple sources by adding the specification of the target population with an associated sampling model; this component guides eligibility, causal models, contrasts, and identification, while the required mapping of data elements from diverse sources onto a single target trial surfaces misalignments that may require switching sources or collecting new data.

What carries the argument

The target trial framework extended by an explicit target population and sampling model, together with the process of mapping data elements from multiple sources onto one emulated trial.

If this is right

  • Eligibility criteria are chosen to align with the defined target population rather than with any single data source.
  • The causal model and the contrasts of interest are specified with the sampling model in view.
  • Identification strategies are selected after the mapping exercise has clarified which assumptions are supportable by the available sources.
  • Analyses that encounter severe misalignments are redirected toward alternative data sources or new data collection.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • The same mapping discipline could be applied to pooled analyses of multiple randomized trials or to meta-analyses that seek causal rather than associational summaries.
  • Regulatory submissions that rely on external comparators might adopt the extended framework to document source selection more systematically.
  • Study protocols could be written first as target trials and only afterward matched to existing data sources, reversing the current sequence.

Load-bearing premise

Mapping data elements from multiple sources onto a single target trial will reliably surface irreconcilable misalignments that can be resolved by switching sources or prospectively obtaining data rather than requiring ad-hoc adjustments.

What would settle it

An applied example in which the mapping step is performed yet irreconcilable misalignments between sources remain undetected and the combined analysis proceeds with ad-hoc adjustments that still yield unbiased causal estimates.

read the original abstract

We describe how the target trial framework can be used to plan and report analyses that attempt to answer causal questions by combining information from multiple, diverse sources. Such analyses may involve comparisons of treatments evaluated in different populations, for example when an index trial is combined with other data sources in external comparator analyses, or when extending causal inferences from a randomized trial to a new target population in generalizability and transportability analyses. When planning such analyses, the specification of the target trial supports the explicit definition of the target population with an associated sampling model. We propose this as an additional component for the target trial framework, especially relevant for analyses that combine information, because it influences the choice of eligibility criteria, the specification of the causal model, the choice of causal contrasts, and reasoning about identification strategies. Furthermore, the framework encourages careful mapping of data elements from multiple data sources to a single target trial. This mapping process can highlight potentially irreconcilable misalignments between data sources with respect to specific components of the framework -- for example, in the definitions of eligibility criteria, treatment assignment, and treatment receipt. Such misalignments can arise when attempts to specify a target trial that aligns with a specific data source introduce or worsen misalignments with other proposed data sources. The extent of such misalignments may warrant switching to other data sources, or prospectively obtaining data, to emulate the proposed target trial. We conclude that the target trial framework promotes transparent discussion about the design of and assumptions made in analyses that answer causal questions by combining information from diverse sources.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

0 major / 2 minor

Summary. The manuscript proposes extending the target trial framework for causal analyses that combine information from multiple data sources (e.g., external comparator analyses or transportability studies). It advocates adding an explicit target population and associated sampling model as a new component, arguing that this guides choices of eligibility criteria, causal model specification, causal contrasts, and identification strategies. The framework is said to encourage systematic mapping of data elements across sources onto a single target trial, which can surface irreconcilable misalignments (e.g., in eligibility, treatment assignment, or outcome definitions) and thereby inform decisions to switch sources or collect new data prospectively.

Significance. If adopted, the proposal offers a structured, transparent approach to multi-source causal inference that builds directly on the existing target trial framework without introducing new parameters, equations, or derivations. By making the population-sampling link explicit and formalizing the mapping process, it could reduce reliance on ad-hoc adjustments and improve early detection of data incompatibilities in fields such as pharmacoepidemiology and comparative effectiveness research. The contribution is primarily conceptual and guidance-oriented rather than empirical or theorem-based.

minor comments (2)
  1. [Abstract] The abstract states that the sampling model 'influences the choice of eligibility criteria' but does not provide a concrete illustration of how the sampling model is formally distinguished from or interacts with the eligibility criteria already required by the standard target trial framework; a brief worked example would strengthen the claim.
  2. The description of the mapping process notes that misalignments 'may warrant switching to other data sources,' but the manuscript does not discuss criteria or thresholds for deciding when a misalignment is irreconcilable versus adjustable within the framework; adding guidance on this decision point would improve practical utility.

Simulated Author's Rebuttal

0 responses · 0 unresolved

We thank the referee for their positive assessment of the manuscript and for recommending minor revision. The referee's summary accurately captures our proposal to extend the target trial framework by making the target population and sampling model explicit when combining information from multiple data sources.

Circularity Check

0 steps flagged

No significant circularity

full rationale

The paper is a purely conceptual methodological proposal for extending the target trial framework to multi-source causal analyses. It contains no equations, derivations, fitted parameters, or quantitative predictions that could reduce to inputs by construction. All load-bearing steps are explicit reasoning about eligibility criteria, sampling models, and data mapping; these do not invoke self-citations as uniqueness theorems or smuggle ansatzes. The framework extension is presented as guidance rather than a derived result, making the argument self-contained against external benchmarks.

Axiom & Free-Parameter Ledger

0 free parameters · 1 axioms · 0 invented entities

The paper relies on the pre-existing target trial framework and standard causal inference assumptions without introducing new free parameters or invented entities.

axioms (1)
  • domain assumption Standard causal inference assumptions (consistency, positivity, exchangeability) remain valid when data elements from multiple sources are mapped to a single target trial.
    The proposal extends the framework without modifying or testing its core identifying assumptions.

pith-pipeline@v0.9.1-grok · 5818 in / 1256 out tokens · 43706 ms · 2026-06-30T13:42:01.223753+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

92 extracted references · 8 canonical work pages · 4 internal anchors

  1. [1]

    Hern´ an, M. A. & Robins, J. M. Using big data to emulate a target trial when a ran- domized trial is not available.American Journal of Epidemiology183,758–764 (2016)

    2016

  2. [2]

    A., Dahabreh, I

    Hern´ an, M. A., Dahabreh, I. J., Dickerman, B. A. & Swanson, S. A. The target trial framework for causal inference from observational data: why and when is it helpful? Annals of Internal Medicine178,402–407 (2025)

    2025

  3. [3]

    Dorn, H. F. Philosophy of inferences from retrospective studies.American Journal of Public Health and the Nations Health43,677–683 (1953)

    1953

  4. [4]

    Causality and econometrics.Econometrica: Journal of the Econometric Soci- ety,162–177 (1954)

    Wold, H. Causality and econometrics.Econometrica: Journal of the Econometric Soci- ety,162–177 (1954)

    1954

  5. [5]

    Cochran, W. G. & Chambers, S. P. The planning of observational studies of human populations.Journal of the Royal Statistical Society. Series A (General)128,234–266 (1965)

    1965

  6. [6]

    Cochran, W. G. Observational studies.Observational Studies1,126–136 (1972, repub- lished in 2015)

    1972

  7. [7]

    Rubin, D. B. Estimating causal effects of treatments in randomized and nonrandomized studies.Journal of Educational Psychology66,688 (1974)

    1974

  8. [8]

    Robins, J. M. A new approach to causal inference in mortality studies with a sus- tained exposure period – application to control of the healthy worker survivor effect. Mathematical Modelling7,1393–1512 (1986)

    1986

  9. [9]

    Horwitz, R. I. The experimental paradigm and observational studies of cause-effect relationships in clinical medicine.Journal of Chronic Diseases40,91–99 (1987)

    1987

  10. [10]

    Robins, J. M. & Morgenstern, H. The foundations of confounding in epidemiology. Computers & Mathematics with Applications14,869–916 (1987). 14

    1987

  11. [11]

    & Greenland, S

    Maldonado, G. & Greenland, S. Estimating causal effects.International Journal of Epidemiology31,422–429 (2002)

    2002

  12. [12]

    J., Greenland, S., Lash, T

    Rothman, K. J., Greenland, S., Lash, T. L.,et al. Modern Epidemiology(Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, 2008)

    2008

  13. [13]

    A., Ackerman, B

    Stuart, E. A., Ackerman, B. & Westreich, D. Generalizability of randomized trial re- sults to target populations: design and analysis possibilities.Research on Social Work Practice28,532–537 (2018)

    2018

  14. [14]

    K., Lesko, C

    Westreich, D., Edwards, J. K., Lesko, C. R., Cole, S. R. & Stuart, E. A. Target validity and the hierarchy of study designs.American Journal of Epidemiology188,438–443 (2019)

    2019

  15. [15]

    J., Matthews, A., Steingrimsson, J

    Dahabreh, I. J., Matthews, A., Steingrimsson, J. A., Scharfstein, D. O. & Stuart, E. A. Using trial and observational data to assess effectiveness: Trial emulation, transporta- bility, benchmarking, and joint analysis.Epidemiologic Reviews,mxac011 (2023)

    2023

  16. [16]

    Gehan, E. A. & Freireich, E. J. Non-randomized controls in cancer clinical trials.New England Journal of Medicine290,198–203 (1974)

    1974

  17. [17]

    Pocock, S. J. The combination of randomized and historical controls in clinical trials. Journal of Chronic Diseases29,175–188 (1976)

    1976

  18. [18]

    Sacks, H., Chalmers, T. C. & Smith, H. Randomized versus historical controls for clinical trials.The American Journal of Medicine72,233–240 (1982)

    1982

  19. [19]

    P., Selwyn, M

    Dempster, A. P., Selwyn, M. R. & Weeks, B. J. Combining historical and random- ized controls for assessing trends in proportions.Journal of the American Statistical Association78,221–227 (1983)

    1983

  20. [20]

    Carrigan, G.et al.Using electronic health records to derive control arms for early phase single-arm lung cancer trials: Proof-of-concept in randomized controlled trials.Clinical Pharmacology & Therapeutics107,369–377 (2020). 15

    2020

  21. [21]

    Tan, K.et al.Emulating control arms for cancer clinical trials using external cohorts created from electronic health record-derived real-world data.Clinical Pharmacology & Therapeutics111,168–178 (2022)

    2022

  22. [22]

    US Food and Drug Administration.Considerations for the design and conduct of ex- ternally controlled trials for drug and biological productsWeb page (2023). Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ considerations-design-and-conduct-externally-controlled-trials-drug-and-biological- products (accessed October 16, 2025)

    2023

  23. [23]

    Hampson, L. V.et al.Combining the target trial and estimand frameworks to define the causal estimand: an application using real-world data to contextualize a single-arm trial.Statistics in Biopharmaceutical Research16,1–10 (2024)

    2024

  24. [24]

    Ung, L., Wang, G., Haneuse, S., Hern´ an, M. A. & Dahabreh, I. J.Identification strate- gies for combining an experimental study with external data2026. arXiv: 2406.03302 [stat.ME]

    work page internal anchor Pith review Pith/arXiv arXiv

  25. [25]

    Constructing external comparator groups via transportability in mean or in effect measure

    Ung, L.et al. Constructing external comparator groups via transportability in mean or in effect measure2026. arXiv: 2604.19977[stat.ME]

    work page internal anchor Pith review Pith/arXiv arXiv

  26. [26]

    Cole, S. R. & Stuart, E. A. Generalizing evidence from randomized clinical trials to target populations: the ACTG 320 trial.American Journal of Epidemiology172,107– 115 (2010)

    2010

  27. [27]

    Perils and potentials of self-selected entry to epidemiolog- ical studies and surveys

    Hern´ an, M. A. Discussion of “Perils and potentials of self-selected entry to epidemiolog- ical studies and surveys”.Journal of the Royal Statistical Society. Series A (Statistics in Society)179,346–347 (2016)

    2016

  28. [28]

    A., Bradshaw, C

    Stuart, E. A., Bradshaw, C. P. & Leaf, P. J. Assessing the generalizability of randomized trial results to target populations.Prevention Science16,475–485 (2015). 16

    2015

  29. [29]

    L.et al.Generalizing evidence from randomized trials using inverse prob- ability of sampling weights.Journal of the Royal Statistical Society

    Buchanan, A. L.et al.Generalizing evidence from randomized trials using inverse prob- ability of sampling weights.Journal of the Royal Statistical Society. Series A (Statistics in Society)181,1193–1209 (2018)

    2018

  30. [30]

    Dahabreh, I. J. & Hern´ an, M. A. Extending inferences from a randomized trial to a target population.European Journal of Epidemiology34,719–722 (2019)

    2019

  31. [31]

    J., Robertson, S

    Dahabreh, I. J., Robertson, S. E., Tchetgen Tchetgen, E. J., Stuart, E. A. & Hern´ an, M. A. Generalizing causal inferences from individuals in randomized trials to all trial- eligible individuals.Biometrics75,685–694 (2019)

    2019

  32. [32]

    J.et al.Study designs for extending causal inferences from a randomized trial to a target population.American Journal of Epidemiology190,1632–1642 (2021)

    Dahabreh, I. J.et al.Study designs for extending causal inferences from a randomized trial to a target population.American Journal of Epidemiology190,1632–1642 (2021)

    2021

  33. [33]

    & Dahabreh, I

    Ung, L. & Dahabreh, I. J. Keep asking: What do I want? What do I have? What do I do? An approach for combining information to learn about a target population. European Journal of Epidemiology,1–10 (2025)

    2025

  34. [34]

    Norvang, V.et al.Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data.BMC Medical Research Methodology22,152 (2022)

    2022

  35. [35]

    Polito, L.et al.Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting.Frontiers in Pharmacology15,1223858 (2024)

    2024

  36. [36]

    & Lee, H

    Arnold, K., Antunes, L., Coles, B. & Lee, H. Application of the target trial emulation framework to external comparator studies.Frontiers in Drug Safety and Regulation4, 1380568 (2024)

    2024

  37. [37]

    Gupta, A.et al.Quantitative bias analysis for single-arm trials with external control arms.JAMA Network Open8,e252152–e252152 (2025)

    2025

  38. [38]

    J.et al.Dabigatran versus warfarin in patients with atrial fibrillation.New England Journal of Medicine361,1139–1151 (2009)

    Connolly, S. J.et al.Dabigatran versus warfarin in patients with atrial fibrillation.New England Journal of Medicine361,1139–1151 (2009). 17

    2009

  39. [39]

    R.et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.New England Journal of Medicine365,883–891 (2011)

    Patel, M. R.et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.New England Journal of Medicine365,883–891 (2011)

    2011

  40. [40]

    J.et al.Apixaban in patients with atrial fibrillation.New England Journal of Medicine364,806–817 (2011)

    Connolly, S. J.et al.Apixaban in patients with atrial fibrillation.New England Journal of Medicine364,806–817 (2011)

    2011

  41. [41]

    P.et al.Edoxaban versus warfarin in patients with atrial fibrillation.New England Journal of Medicine369,2093–2104 (2013)

    Giugliano, R. P.et al.Edoxaban versus warfarin in patients with atrial fibrillation.New England Journal of Medicine369,2093–2104 (2013)

    2093

  42. [42]

    A., Dickerman, B

    Hern´ an, M. A., Dickerman, B. A., Swanson, S. A. & Dahabreh, I. J. Where do target trials come from? Specifying the protocol of a target trial when repurposing data for causal inference.Epidemiology37,282–286 (2026)

    2026

  43. [43]

    K., Lesko, C

    Westreich, D., Edwards, J. K., Lesko, C. R., Stuart, E. & Cole, S. R. Transportability of trial results using inverse odds of sampling weights.American Journal of Epidemiology 186,1010–1014 (2017)

    2017

  44. [44]

    J., Robertson, S

    Dahabreh, I. J., Robertson, S. E. & Hern´ an, M. A. On the relation between g-formula and inverse probability weighting estimators for generalizing trial results.Epidemiology 30,807–812 (2019)

    2019

  45. [45]

    Ventz, S.et al.The design and evaluation of hybrid controlled trials that leverage external data and randomization.Nature Communications13,5783 (2022)

    2022

  46. [46]

    & Zhou, X.-H

    Li, X., Miao, W., Lu, F. & Zhou, X.-H. Improving efficiency of inference in clinical trials with external control data.Biometrics79,394–403 (2023)

    2023

  47. [47]

    J., Robertson, S

    Dahabreh, I. J., Robertson, S. E., Petito, L. C., Hern´ an, M. A. & Steingrimsson, J. A. Efficient and robust methods for causally interpretable meta-analysis: Transporting inferences from multiple randomized trials to a target population.Biometrics79,1057– 1072 (2023)

    2023

  48. [48]

    D., Krijthe, J

    Karlsson, R., Wang, G., Bartolomeis, P. D., Krijthe, J. H. & Dahabreh, I. J.Ro- bust integration of external control data in randomized trials2025. arXiv: 2406.17971 [stat.ME]. 18

    work page arXiv

  49. [49]

    Valancius, M.et al.A causal inference framework for leveraging external controls in hybrid trials.Biometrics80,ujae095 (2024)

    2024

  50. [50]

    E.et al.Experiment-selector cross-validated targeted maximum likelihood es- timator for hybrid RCT-external data studies.Journal of Causal Inference13,20240041 (2025)

    Dang, L. E.et al.Experiment-selector cross-validated targeted maximum likelihood es- timator for hybrid RCT-external data studies.Journal of Causal Inference13,20240041 (2025)

    2025

  51. [51]

    Advances in Neural Information Processing Systems38,159470–159509 (2026)

    De Bartolomeis, P.et al.Efficient randomized experiments using foundation models. Advances in Neural Information Processing Systems38,159470–159509 (2026)

    2026

  52. [52]

    Externally Controlled Trials: A Review of Design and Borrowing Through a Causal Lens

    Zhu, K.et al. Externally controlled trials: A review of design and borrowing through a causal lens2026. arXiv: 2605.03282[stat.ME]

    work page internal anchor Pith review Pith/arXiv arXiv

  53. [53]

    Robins, J. M. Covariance adjustment in randomized experiments and observational studies: Comment.Statistical Science17,309–321 (2002)

    2002

  54. [54]

    Dahabreh, I. J. Invited commentary: combining information to answer epidemiologic questions about a target population.American Journal of Epidemiology193,741–750 (2024)

    2024

  55. [55]

    A.External controls: Emulating half of the target trial.European Medicines Agency workshop on the use of external controls for evidence generation in regulatory decision-making

    Hern´ an, M. A.External controls: Emulating half of the target trial.European Medicines Agency workshop on the use of external controls for evidence generation in regulatory decision-making. Web page (2025). Available at: https://www.ema.europa.eu/en/ documents/presentation/presentation-external-controls-emulation-half-target-trial-m- hernan en.pdf (acces...

    2025

  56. [56]

    A., Garc´ ıa-Alb´ eniz, X

    Dickerman, B. A., Garc´ ıa-Alb´ eniz, X. & Hern´ an, M. A. Target trial emulation for regulatory and clinical decision making in cancer.Journal of Clinical Oncology44, 1139–1144 (2026)

    2026

  57. [57]

    Gage, B. F.et al.Validation of clinical classification schemes for predicting stroke: re- sults from the National Registry of Atrial Fibrillation.Journal of the American Medical Association285,2864–2870 (2001). 19

    2001

  58. [58]

    Ray, W. A. Evaluating medication effects outside of clinical trials: new-user designs. American Journal of Epidemiology158,915–920 (2003)

    2003

  59. [59]

    Schneeweiss, S.et al.Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results.Medical Care45,S131– S142 (2007)

    2007

  60. [60]

    L., Richardson, D

    Lund, J. L., Richardson, D. B. & St¨ urmer, T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Current Epidemiology Reports2,221–228 (2015)

    2015

  61. [61]

    Yoshida, K., Solomon, D. H. & Kim, S. C. Active-comparator design and new-user design in observational studies.Nature Reviews Rheumatology11,437–441 (2015)

    2015

  62. [62]

    & Suissa, S

    Schneeweiss, S. & Suissa, S. Advanced approaches to controlling confounding in phar- macoepidemiologic studies.Pharmacoepidemiology,1078–1107 (2019)

    2019

  63. [63]

    A., Kalager, M

    Huitfeldt, A., Hernan, M. A., Kalager, M. & Robins, J. M. Comparative effectiveness research using observational data: active comparators to emulate target trials with inactive comparators.EGEMs4(2016)

    2016

  64. [64]

    Epidemiology31,636–643 (2020)

    Chiu, Y.-H.et al.The effect of prenatal treatments on offspring events in the pres- ence of competing events: an application to a randomized trial of fertility therapies. Epidemiology31,636–643 (2020)

    2020

  65. [65]

    A., Robins, J

    Hern´ an, M. A., Robins, J. M.,et al.Per-protocol analyses of pragmatic trials.New England Journal of Medicine377,1391–1398 (2017)

    2017

  66. [66]

    J., Ung, L., Hern´ an, M

    Dahabreh, I. J., Ung, L., Hern´ an, M. A. & Chiu, Y. H.The role of assignment in defining and identifying causal effects in randomized trials2025. arXiv: 2408.14710 [stat.ME]

    work page arXiv

  67. [67]

    Further remarks concerning the consistency assumption.Epidemiology 20,880–883 (2009)

    VanderWeele, T. Further remarks concerning the consistency assumption.Epidemiology 20,880–883 (2009). 20

    2009

  68. [68]

    & Bareinboim, E.Transportability of causal and statistical relations: a for- mal approachin2011 IEEE 11th International Conference on Data Mining Workshops (2011), 540–547

    Pearl, J. & Bareinboim, E.Transportability of causal and statistical relations: a for- mal approachin2011 IEEE 11th International Conference on Data Mining Workshops (2011), 540–547

    2011

  69. [69]

    & Pearl, J

    Bareinboim, E. & Pearl, J. Causal inference and the data-fusion problem.Proceedings of the National Academy of Sciences113,7345–7352 (2016)

    2016

  70. [70]

    J., Robins, J

    Dahabreh, I. J., Robins, J. M., Haneuse, S. J.-P. A. & Hern´ an, M. A.Generalizing causal inferences from randomized trials: counterfactual and graphical identification

  71. [71]

    arXiv: 1906.10792[stat.ME]

    work page internal anchor Pith review Pith/arXiv arXiv 1906

  72. [72]

    J., Robins, J

    Dahabreh, I. J., Robins, J. M. & Hern´ an, M. A. Benchmarking observational methods by comparing randomized trials and their emulations.Epidemiology31,614–619 (2020)

    2020

  73. [73]

    J., Robertson, S

    Dahabreh, I. J., Robertson, S. E., Steingrimsson, J. A., Stuart, E. A. & Hern´ an, M. A. Extending inferences from a randomized trial to a new target population.Statistics in Medicine39,1999–2014 (2020)

    1999

  74. [74]

    Ung, L., VanderWeele, T. J. & Dahabreh, I. J. Generalizing and transporting causal inferences from randomized trials in the presence of trial engagement effects.Epidemi- ology36,500–510 (2025)

    2025

  75. [75]

    A.Hawthorne revisited: Management and the worker, its critics, and developments in human relations in industry(Cornell University, Ithaca, NY, 1958)

    Landsberger, H. A.Hawthorne revisited: Management and the worker, its critics, and developments in human relations in industry(Cornell University, Ithaca, NY, 1958)

    1958

  76. [76]

    & Greenwood, N

    Sedgwick, P. & Greenwood, N. Understanding the Hawthorne effect.British Medical Journal351(2015)

    2015

  77. [77]

    J., Robertson, S

    Dahabreh, I. J., Robertson, S. E. & Hern´ an, M. A.Generalizing and transporting infer- ences about the effects of treatment assignment subject to non-adherence2022. arXiv: 2211.04876[stat.ME]

    work page arXiv

  78. [78]

    & Bareinboim, E

    Pearl, J. & Bareinboim, E. External validity: from do-calculus to transportability across populations.Statistical Science29,579–595 (2014). 21

    2014

  79. [79]

    & Pearl, J.Transportability of causal effects: completeness resultsin Proceedings of the Twenty-Sixth AAAI Conference on Artificial Intelligence(2012), 698–704

    Bareinboim, E. & Pearl, J.Transportability of causal effects: completeness resultsin Proceedings of the Twenty-Sixth AAAI Conference on Artificial Intelligence(2012), 698–704

    2012

  80. [80]

    Rubin, D. B. Which ifs have causal answers.Journal of the American Statistical Asso- ciation81,961–962 (1986)

    1986

Showing first 80 references.